Latest Ratios: P/E Ratio -0.2x · EV/EBITDA N/A · ROE -1599.4%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $10M | $26M | $23M | — | — | — |
| Enterprise Value | $5M | $22M | $20M | — | — | — |
| P/E Ratio → | -0.23 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 213.06 | 708.66 | 7.46 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -1599.4% | -1599.4% | -525.4% | -478.2% | — | — |
| ROA | -323.0% | -323.0% | -295.9% | -488.6% | -937.2% | -2617.7% |
| ROIC | — | — | — | — | — | — |
| ROCE | -1059.5% | -1059.5% | -502.3% | -425.6% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 107.09 | 107.09 | 0.10 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -126.23 | -1.23 | -1.55 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -129.91 | -129.91 | -35.13 | -4.46 | -2.21 | -16.81 |
Net cash position: cash ($9M) exceeds total debt ($4M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.00 | 1.00 | 2.33 | 2.42 | 0.02 | 0.01 |
| Quick Ratio | 1.00 | 1.00 | 2.33 | 2.42 | 0.02 | 0.01 |
| Cash Ratio | 0.88 | 0.88 | 1.81 | 2.20 | 0.02 | 0.01 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $17M | $10M | $5M | $8M | $8M |
Clinical-stage liquidity shortfall
As reported in financial statements, MDCX's P/B ratio of 212.14 significantly exceeds typical biotech benchmarks, suggesting that the market is pricing the firm based on speculative intellectual property potential rather than tangible book value, which has been eroded by persistent operating losses and capital consumption.
The extreme P/B multiple indicates that investors are assigning value almost exclusively to the SkinJect platform's future clinical success. Given the lack of revenue and negative earnings, traditional valuation metrics like P/E are non-informative, and the current pricing appears to reflect a high-risk, binary outcome scenario where the company's survival is contingent on future capital raises.
Based on historical quarterly data, MDCX has consistently posted negative ROIC figures, such as the -186.1% observed in 2024Q3, illustrating that the company is currently destroying invested capital as it funds R&D without generating any offsetting operational income or commercial returns.
The inability to generate positive returns on capital is a structural reality for a pre-revenue firm, but the magnitude of these negative returns highlights the high cost of clinical development. Investors should monitor whether future trial milestones can eventually pivot these metrics toward a positive trajectory, though current trends suggest significant ongoing capital destruction.
According to recent SEC filings, MDCX's debt-to-equity ratio reached a peak of 146.80 in 2025Q4, indicating a highly leveraged capital structure that leaves the firm with minimal room for error as it navigates the expensive and uncertain path of clinical trial completion.
The reliance on debt in a pre-revenue context is particularly concerning, as it introduces interest service obligations that further strain the company's limited cash reserves. This leverage profile suggests that the company may face significant refinancing risks or be forced into highly dilutive equity financing to satisfy creditors.
As indicated by the provided financial data, the current ratio has compressed from 4.11 in 2024Q2 to 1.22 in 2026Q1, signaling that the company's liquidity cushion is rapidly depleting as it funds its ongoing research and development activities without a recurring revenue stream.
The decline in the current ratio suggests that the company's ability to meet short-term obligations is becoming increasingly sensitive to the timing of capital raises. Without a clear path to commercialization, the current liquidity position warrants close monitoring, as any delay in clinical milestones could lead to a rapid exhaustion of available cash.
Based on an analysis of the company's financial structure, the current ratio is frequently misapplied as a measure of stability, whereas for MDCX, it obscures the reality that the firm is essentially a cash-burning entity with no operational cash flow to support its debt obligations.
Investors often view a current ratio above 1.0 as a sign of health, but in this case, it merely reflects the temporary presence of cash from previous financing rounds. A more appropriate metric would be the 'cash burn rate' relative to the remaining runway, as the current ratio fails to account for the lack of sustainable, self-funding operations.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MDCX stock.
Medicus Pharma Ltd. Common Stock's current P/E ratio is -0.2x. This places it at the 50th percentile of its historical range.
Medicus Pharma Ltd. Common Stock's return on equity (ROE) is -1599.4%. The historical average is -478.2%.
Based on historical data, Medicus Pharma Ltd. Common Stock is trading at a P/E of -0.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.